Literature DB >> 8018463

Clinical evaluation of pain during subcutaneous injections of low molecular weight heparins in healthy volunteers.

N Billon1, F Gloaguen, C Funck-Brentano, P Jaillon.   

Abstract

In order to compare the intensity and the duration of the pain following the subcutaneous injection of low molecular weight heparins, 0.4 ml nadroparin, 0.4 ml enoxaparin and 0.4 ml placebo (NaCl 0.9%) were administered at 1 week intervals to 12 healthy volunteers in a randomised, double-blind, three-period study. Pain was assessed by visual analogue and verbal category scales. Based on visual analogue scale scores, nadroparin resulted in significantly less pain than enoxaprin at 1 and 5 min after injection (6.2 +/- 2.6 mm vs 21.9 +/- 5.9 mm; P < 0.05 and 3.5 + 1.5 mm vs 14.3 +/- 4 mm; P < 0.05, respectively, mean +/- s.e. mean). Similar results were obtained using verbal category scale. Confidence interval testing for difference between groups showed that nadroparin injection resulted in less pain than enoxaparin at 1 min (-15.8: -31.2 to -0.4 mm).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018463      PMCID: PMC1364743          DOI: 10.1111/j.1365-2125.1994.tb04296.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  1 in total

1.  [Local tolerance of subcutaneous heparin. Double-blind comparison of calcium and sodium heparins (author's transl)].

Authors:  J M Blard; F Rincon; J P Nakache; C Chastang
Journal:  Sem Hop       Date:  1979 Jan 8-15
  1 in total
  2 in total

Review 1.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

2.  Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism.

Authors:  Sake J van der Wall; Frederikus A Klok; Paul L den Exter; Deisy Barrios; Raquel Morillo; Suzanne C Cannegieter; David Jimenez; Menno V Huisman
Journal:  Hemasphere       Date:  2018-02-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.